SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE L impact

Wedbush maintains Ultragenyx Pharma neutral, cuts $23 target

Wedbush maintains a neutral rating on Ultragenyx Pharma and cuts its price target to $23.00 from $30.00,

RARE

Ratings actions GMT) Ultragenyx Pharma Price Target Cut to $23.00/Share From $30.00 by WedbushRatings actions